Adalimumab and Anti-Adalimumab Antibody, DoseASSURE™ ADL
Also known as: Anti-TNF-α Drug, DoseASSURE, Humira®
Use
Monitor antiadalimumab therapy for individuals with Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or other autoimmune conditions. This test provides adalimumab drug concentration levels as well as the level of antiadalimumab antibodies.
Special Instructions
Allow a minimum clotting time of 30 to 60 minutes and separate the serum within 2 hours of collection. Send the serum in a plastic transport tube to avoid delays in turnaround time. Use separate frozen specimens for multiple tests on frozen samples, and refrigerate or freeze the specimen as needed.
Limitations
In the presence of antiadalimumab antibodies, the adalimumab level only reflects the antibody-unbound fraction of adalimumab. The absence of antiadalimumab antibodies does not guarantee a positive response to the treatment. Furthermore, failure of adalimumab therapy may not be solely attributed to antiadalimumab antibodies presence.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 99781-7
- 74117-3
- 74116-5
Result Turnaround Time
6-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube.
Storage Instructions
Refrigerate or freeze.
Causes for Rejection
Plasma specimen received
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
| Frozen | 308 days |